{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T08:21:26Z","timestamp":1782548486394,"version":"3.54.5"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81702809"],"award-info":[{"award-number":["81702809"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"DOI":"10.1007\/s00432-025-06132-x","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T03:27:58Z","timestamp":1739503678000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["De Novo MET-amplified NSCLC treated with savolitinib achieved remarkable tumor regression: a case report and review of literature"],"prefix":"10.1007","volume":"151","author":[{"given":"Jin","family":"Sheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongming","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,14]]},"reference":[{"issue":"7","key":"6132_CR1","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1200\/JCO.2015.63.4600","volume":"34","author":"MM Awad","year":"2016","unstructured":"Awad MM, Oxnard GR, Jackman DM, Savukoski DO, Hall D, Shivdasani P et al (2016) MET exon 14 mutations in Non-small-cell Lung Cancer are Associated with Advanced Age and Stage-Dependent MET genomic amplification and c-Met overexpression. J Clin Oncol 34(7):721\u2013730. https:\/\/doi.org\/10.1200\/JCO.2015.63.4600","journal-title":"J Clin Oncol"},{"issue":"6","key":"6132_CR2","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.jtho.2021.02.010","volume":"16","author":"DR Camidge","year":"2021","unstructured":"Camidge DR, Otterson GA, Clark JW, Ignatius Ou SH, Weiss J, Ades S et al (2021) Crizotinib in patients with MET-Amplified NSCLC. J Thorac Oncol 16(6):1017\u20131029. https:\/\/doi.org\/10.1016\/j.jtho.2021.02.010","journal-title":"J Thorac Oncol"},{"issue":"10","key":"6132_CR3","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1200\/JCO.2008.19.1635","volume":"27","author":"F Cappuzzo","year":"2009","unstructured":"Cappuzzo F, Marchetti A, Skokan M, Rossi E, Gajapathy S, Felicioni L et al (2009) Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 27(10):1667\u20131674. https:\/\/doi.org\/10.1200\/JCO.2008.19.1635","journal-title":"J Clin Oncol"},{"issue":"5","key":"6132_CR4","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.jtho.2021.01.1605","volume":"16","author":"I Dagogo-Jack","year":"2021","unstructured":"Dagogo-Jack I, Moonsamy P, Gainor JF, Lennerz JK, Piotrowska Z, Lin JJ et al (2021) A phase 2 study of Capmatinib in patients with MET-Altered Lung Cancer previously treated with a MET inhibitor. J Thorac Oncol 16(5):850\u2013859. https:\/\/doi.org\/10.1016\/j.jtho.2021.01.1605","journal-title":"J Thorac Oncol"},{"issue":"2","key":"6132_CR5","first-page":"147","volume":"1","author":"MF Di Renzo","year":"1995","unstructured":"Di Renzo MF, Olivero M, Giacomini A, Porte H, Chastre E, Mirossay L et al (1995) Overexpression and amplification of the met\/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res 1(2):147\u2013154","journal-title":"Clin Cancer Res"},{"issue":"4","key":"6132_CR6","doi-asserted-by":"publisher","first-page":"340","DOI":"10.6004\/jnccn.2023.0020","volume":"21","author":"DS Ettinger","year":"2023","unstructured":"Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A et al (2023) NCCN Guidelines\u00ae Insights: Non-small Cell Lung Cancer, Version 2.2023. J Natl Compr Canc Netw 21(4):340\u2013350. https:\/\/doi.org\/10.6004\/jnccn.2023.0020","journal-title":"J Natl Compr Canc Netw"},{"key":"6132_CR7","doi-asserted-by":"publisher","unstructured":"Gu Y, Sai Y, Wang J, Yu M, Wang G, Zhang L et al (2019) Preclinical pharmacokinetics, disposition, and translational pharmacokinetic\/pharmacodynamic modeling of savolitinib, a novel selective cMet inhibitor. Eur J Pharm Sci 136104938. https:\/\/doi.org\/10.1016\/j.ejps.2019.05.016","DOI":"10.1016\/j.ejps.2019.05.016"},{"issue":"1","key":"6132_CR8","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1158\/2159-8290.CD-22-0586","volume":"13","author":"RJ Hartmaier","year":"2023","unstructured":"Hartmaier RJ, Markovets AA, Ahn MJ, Sequist LV, Han JY, Cho BC et al (2023) Osimertinib\u2009+\u2009savolitinib to overcome acquired MET-Mediated resistance in epidermal growth factor Receptor-Mutated, MET-Amplified Non-small Cell Lung Cancer: TATTON. Cancer Discov 13(1):98\u2013113. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-0586","journal-title":"Cancer Discov"},{"issue":"5","key":"6132_CR10","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.3390\/curroncol28050317","volume":"28","author":"Y Kumaki","year":"2021","unstructured":"Kumaki Y, Olsen S, Suenaga M, Nakagawa T, Uetake H, Ikeda S (2021) Comprehensive genomic profiling of circulating cell-free DNA distinguishes focal MET amplification from Aneuploidy in Diverse Advanced cancers. Curr Oncol 28(5):3717\u20133728. https:\/\/doi.org\/10.3390\/curroncol28050317","journal-title":"Curr Oncol"},{"issue":"18","key":"6132_CR9","doi-asserted-by":"publisher","first-page":"4552","DOI":"10.3390\/cancers15184552","volume":"15","author":"Y Kumaki","year":"2023","unstructured":"Kumaki Y, Oda G, Ikeda S (2023) Targeting MET amplification: opportunities and obstacles in therapeutic approaches. Cancers (Basel) 15(18):4552. https:\/\/doi.org\/10.3390\/cancers15184552","journal-title":"Cancers (Basel)"},{"issue":"10","key":"6132_CR11","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/S2213-2600(21)00084-9","volume":"9","author":"S Lu","year":"2021","unstructured":"Lu S, Fang J, Li X, Cao L, Zhou J, Guo Q et al (2021) Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study. Lancet Respir Med 9(10):1154\u20131164. https:\/\/doi.org\/10.1016\/S2213-2600(21)00084-9","journal-title":"Lancet Respir Med"},{"issue":"13","key":"6132_CR12","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1111\/1759-7714.14848","volume":"14","author":"K Miao","year":"2023","unstructured":"Miao K, Zhang X, Wang H, Si X, Zhang L (2023) Savolitinib versus crizotinib for treating MET positive non-small cell lung cancer. Thorac Cancer 14(13):1162\u20131170. https:\/\/doi.org\/10.1111\/1759-7714.14848","journal-title":"Thorac Cancer"},{"issue":"12","key":"6132_CR13","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1093\/annonc\/mdz407","volume":"30","author":"D Moro-Sibilot","year":"2019","unstructured":"Moro-Sibilot D, Cozic N, P\u00e9rol M, Mazi\u00e8res J, Otto J, Souquet PJ et al (2019) Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcS\u00e9 phase II trial. Ann Oncol 30(12):1985\u20131991. https:\/\/doi.org\/10.1093\/annonc\/mdz407","journal-title":"Ann Oncol"},{"issue":"9","key":"6132_CR14","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1002\/(sici)1097-0142(19990501)85:9<1894::aid-cncr3>3.0.co;2-j","volume":"85","author":"M Nakajima","year":"1999","unstructured":"Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, Yamashita J et al (1999) The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 85(9):1894\u20131902. https:\/\/doi.org\/10.1002\/(sici)1097-0142(19990501)85:9%3C1894::aid-cncr3%3E3.0.co;2-j","journal-title":"Cancer"},{"issue":"10","key":"6132_CR15","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1056\/NEJMoa2004407","volume":"383","author":"PK Paik","year":"2020","unstructured":"Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC et al (2020) Tepotinib in Non-small-cell Lung Cancer with MET exon 14 skipping mutations. N Engl J Med 383(10):931\u2013943. https:\/\/doi.org\/10.1056\/NEJMoa2004407","journal-title":"N Engl J Med"},{"issue":"1","key":"6132_CR16","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s40164-021-00245-y","volume":"10","author":"LX Peng","year":"2021","unstructured":"Peng LX, Jie GL, Li AN, Liu SY, Sun H, Zheng MM et al (2021) MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors. Exp Hematol Oncol 10(1):52. https:\/\/doi.org\/10.1186\/s40164-021-00245-y","journal-title":"Exp Hematol Oncol"},{"issue":"7","key":"6132_CR17","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1158\/2159-8290.CD-19-1446","volume":"10","author":"G Recondo","year":"2020","unstructured":"Recondo G, Che J, J\u00e4nne PA, Awad MM (2020) Targeting MET dysregulation in Cancer. Cancer Discov 10(7):922\u2013934. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-1446","journal-title":"Cancer Discov"},{"issue":"3","key":"6132_CR18","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S1470-2045(19)30785-5","volume":"21","author":"LV Sequist","year":"2020","unstructured":"Sequist LV, Han JY, Ahn MJ, Cho BC, Yu H, Kim SW et al (2020) Osimertinib plus Savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol 21(3):373\u2013386. https:\/\/doi.org\/10.1016\/S1470-2045(19)30785-5","journal-title":"Lancet Oncol"},{"issue":"2","key":"6132_CR19","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.cllc.2016.09.011","volume":"18","author":"Z Song","year":"2017","unstructured":"Song Z, Wang X, Zheng Y, Su H, Zhang Y (2017) MET gene amplification and overexpression in Chinese non-small-cell lung Cancer patients without EGFR mutations. Clin Lung Cancer 18(2):213\u2013219e2. https:\/\/doi.org\/10.1016\/j.cllc.2016.09.011","journal-title":"Clin Lung Cancer"},{"issue":"12","key":"6132_CR20","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/nrm3012","volume":"11","author":"L Trusolino","year":"2010","unstructured":"Trusolino L, Bertotti A, Comoglio PM (2010) MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 11(12):834\u2013848. https:\/\/doi.org\/10.1038\/nrm3012","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"8","key":"6132_CR21","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1080\/14737140.2019.1643239","volume":"19","author":"JF Vansteenkiste","year":"2019","unstructured":"Vansteenkiste JF, Van De Kerkhove C, Wauters E, Van Mol P (2019) Capmatinib for the treatment of non-small cell lung cancer. Expert Rev Anticancer Ther 19(8):659\u2013671. https:\/\/doi.org\/10.1080\/14737140.2019.1643239","journal-title":"Expert Rev Anticancer Ther"},{"key":"6132_CR22","doi-asserted-by":"publisher","unstructured":"Wolf J, Overbeck TR, Han JY, Hochmair M, de Marinis F, Ohashi K et al (2020a) Capmatinib in patients with high-level MET -amplified advanced non\u2013small cell lung cancer (NSCLC): results from the phase 2 GEOMETRY mono-1 study. J Clin Oncol 38(15):9509\u20139509. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.9509","DOI":"10.1200\/JCO.2020.38.15_suppl.9509"},{"issue":"10","key":"6132_CR23","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1056\/NEJMoa2002787","volume":"383","author":"J Wolf","year":"2020","unstructured":"Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen H et al (2020b) Capmatinib in MET exon 14-Mutated or MET-Amplified non-small-cell Lung Cancer. N Engl J Med 383(10):944\u2013957. https:\/\/doi.org\/10.1056\/NEJMoa2002787","journal-title":"N Engl J Med"},{"issue":"11","key":"6132_CR24","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/S2213-2600(20)30154-5","volume":"8","author":"YL Wu","year":"2020","unstructured":"Wu YL, Cheng Y, Zhou J, Lu S, Zhang Y, Zhao J et al (2020) Tepotinib plus Gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b\/2, multicentre, randomised trial. Lancet Respir Med 8(11):1132\u20131143. https:\/\/doi.org\/10.1016\/S2213-2600(20)30154-5","journal-title":"Lancet Respir Med"},{"key":"6132_CR25","doi-asserted-by":"publisher","unstructured":"Xiuning Le LP, Van Meerbeeck J, Carlos Cabrera Galvez SVR, Young-Chul Kim DVB, Christopher Stroh JK, Rolf Bruns DJ (2022a) 01, GO Clinical response to tepotinib according to circulating tumor (ct) DNA biomarkers in patients with advanced NSCLC with high-level MET amplification (METamp) detected by liquid biopsy (LBx). https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.9121 Journal of Clinical Oncology 40, no. 16_suppl (June 9121\u20139121","DOI":"10.1200\/JCO.2022.40.16_suppl.9121"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06132-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-025-06132-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06132-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T21:29:23Z","timestamp":1741814963000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-025-06132-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,14]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["6132"],"URL":"https:\/\/doi.org\/10.1007\/s00432-025-06132-x","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,14]]},"assertion":[{"value":"30 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Medical Ethical Committee of Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University and the study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. In this case, all patient data and images were published with their written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The included patient gave his oral and written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"82"}}